Search

Your search keyword '"Panaccione R"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Panaccione R" Remove constraint Author: "Panaccione R" Topic anti-inflammatory agents Remove constraint Topic: anti-inflammatory agents
37 results on '"Panaccione R"'

Search Results

1. Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force.

2. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.

3. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

4. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.

5. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

6. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

7. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

8. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

9. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.

10. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.

11. Clinical predictors of thiopurine-related adverse events in Crohn's disease.

12. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.

13. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.

14. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease.

15. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

17. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

18. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.

19. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus.

20. Implementing changes in clinical practice to improve the management of Crohn's disease.

21. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

22. Medical management of inflammatory bowel disease among Canadian gastroenterologists.

23. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

24. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.

25. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

26. Managing the risks of IBD therapy.

27. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.

28. Adalimumab safety in global clinical trials of patients with Crohn's disease.

29. Adalimumab for the treatment of fistulas in patients with Crohn's disease.

30. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

31. Use of combination therapy in IBD.

32. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.

33. Review and clinical perspectives for the use of infliximab in ulcerative colitis.

34. Refractory Crohn's disease of the vulva treated with infliximab: a case report.

35. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

36. Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases

37. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease

Catalog

Books, media, physical & digital resources